Rating: Cautiously Bullish Target Price: RMB 33.5 – 36.9 (Base case: 2026E year-end embedded value per share of RMB 67.04 × P/EV of 0.50–0.55x) Current Price: RMB 29.56 (A-share close, 2026-10-27) Margin of Safety: ~13.3% (base-case fair value floor of RMB 33.5 vs. current price) Time Horizon: 12–18 months
CPIC's A-shares have fallen 34% year-to-date and are near their 52-week low. This report judges that current pricing implies a "permanent spread-loss" scenario: total market cap of RMB 284.4bn is below parent-attributable net assets of RMB 319.2bn; even if the value of the existing life insurance business (value of in-force business of RMB 250.8bn) were written down entirely to zero, the market cap would still be about 11% below net assets — implying the market has discounted roughly 114% of the value of in-force business, which back-solves to a long-term investment yield of only about 1.2%–1.4%, below the 10-year CGB yield of 1.63%. Yet fundamentals have not deteriorated to that degree: in H1 2026, new business value +12.7%, P&C combined ratio 95.0%, parent-attributable operating profit +6.2%, embedded value +3.8% vs. beginning of year, and 2025 full-year ROE of 18.0%. This report is cautiously bullish: base case fair value of RMB 33.5–36.9 over 12–18 months (+13% to +25% vs. current price), with a probability-weighted expected value of about RMB 34.81. Two core constraints: first, if the 10Y CGB yield breaks below 1.5% and triggers a formal downward revision of the EV investment yield assumption (4.0%), the entire valuation anchor will shift lower — under that scenario fair value falls back to roughly RMB 30–33, and the "cheapness" would be shown to be partly assumption-driven; second, 2026 reported net profit will be hit by the equity market correction (sell-side forecasts imply Q3 single-quarter YoY of about -76%), and short-term earnings volatility will keep weighing on sentiment. The Q3 report, disclosed after market close on this report's date (2026-10-28), is the first validation checkpoint.
The opportunity in one sentence: After the Q3 earnings negative (sell-side consensus implies Q3 parent-attributable -76.3%) lands, if the combination of 0.45x P/EV + TTM dividend yield of 5.31% is confirmed by "rate stabilization + no downward revision of EV assumptions in the March 2027 annual report," there is a directional opportunity to re-rate toward 0.50–0.55x P/EV; if the 10Y CGB yield breaks below 1.5% or assumptions are revised down, the thesis is falsified. Evidence strength: Grade B (valuation and operating data traceable to original filings, but the key premise — "no downward revision of EV assumptions" — cannot be verified until March 2027).
Current market environment: Neutral. The insurance sector is in a correction/digestion phase after the big 2025 rally (sector +30.5%), and the 2026 pricing narrative has switched from "liability-side recovery" back to "spread loss."
Key changes over the next 6–12 months:
| Change | From | To | Timing |
|---|---|---|---|
| Q3 profit uncertainty | Sell-side consensus Q3 single-quarter -76.3% (CPIC's 7.4% October decline has partially priced this in) | Actual results land; negative cleared and low base confirmed | After close on 2026-10-28 and the week following the earnings call |
| EV assumption gap | Reported assumption 4.0% vs. actual net investment yield annualized ~3.0%, a gap of ~100bp | One of two resolutions: rates stabilize → discount narrows; or annual report revises assumptions down → one-off VIF hit of -27.4% (-50bp sensitivity) | 2027-03 annual report |
| Shareholder returns | Annual-only dividend, payout ratio stepped down for three years, buyback unexecuted for 18 months | Interim dividend of RMB 0.42/share already paid; FY2026 DPS expected at RMB 1.15–1.22 | 2027-03 annual report dividend plan |
Primary share-price driver: Repricing of the P/EV multiple by long-end rates and the spread-loss narrative (current 0.45x is the lowest among the five major A-share insurers: China Life 0.67 / Ping An 0.64 / NCI 0.55).
Demonstrable expectation gap: The current price implies a long-term investment yield of about 1.2%–1.4% (below the risk-free rate), whereas the company's three-year average investment yield (company basis) is 4.9%, 2025 net investment yield 3.4%, and operating profit is still growing — reality sits between the "reported assumption of 4.0%" and the "market-implied 1.4%," and significantly closer to the former. On the other side, sell-side consensus FY2026 EPS of RMB 6.01 (implying parent-attributable profit of about RMB 57.8bn) has not been revised for nearly 90 days, and its implied Q4 single-quarter profit of RMB 22.8bn (+192% YoY) is arithmetically unattainable — a stale target. The market is mispricing on both ends; the price side (0.45x P/EV) is closer to a defensible anchor than the earnings side (sell-side forecasts).
Validation catalysts and falsification conditions: Validation: 10Y yield stabilizes above 1.6%, annualized net investment yield recovers to 3.2%+, no downward revision of EV assumptions in the 2026 annual report, DPS no lower than RMB 1.15. Falsification: 10Y breaks below 1.5%, annual report revises down investment yield assumptions, NBV negative for two consecutive periods, life insurance comprehensive solvency ratio falls below 180%. See the tracking section at the end for details.
The current price of RMB 29.56 corresponds to P/EV of 0.446x and P/B of 0.89x (at the 3rd, 6th, and 3rd percentiles of the past 3, 5, and 10 years respectively — the lowest range). On a frozen-anchor basis, total market cap of RMB 284.377bn is about RMB 34.8bn below parent-attributable net assets of RMB 319.196bn at end-2026H1: even if the value of in-force business (RMB 250.765bn, RMB 26.07 per share) were written to zero, market cap would still be about 11% below net assets — the market's implied pricing of future profits from the existing book is negative. Extrapolating linearly from the 2025 annual report sensitivity, this discount implies a long-term investment yield of about 1.2%–1.4% (consistent with peer-calibrated cross-checks), below the 10Y CGB yield of 1.63% — i.e., the market is demanding that "CPIC's long-term investing cannot even beat the risk-free rate, and that this state is permanent."
Two caveats on this calculation must be stated honestly: first, the sensitivity extrapolation is a linear approximation; VIF sensitivity to the investment yield is nonlinear under large assumption shifts, and the true implied yield reading could be higher than 1.4%; second, comparing against the "three-year average investment yield of 4.9%" (the company's own disclosure basis in the 2026 interim report, which includes 2024–2025 equity mark-to-market gains) exaggerates the gap; the more sustainable benchmark is the net investment yield (3.4% in 2025, un-annualized 1.5% in 2026H1). But even on the most conservative basis, the market-implied yield (~1.4%–2%) remains significantly below both the 4.0% reported assumption and the 3.4% realized net investment yield — directional excessive bearishness holds. Moreover, the "-RMB 2.597bn investment return variance" in the 2025 EV movement table shows that even in a bull-market year, actual investment returns fell short of assumptions — the real issue is not "the market is entirely wrong," but that "the 4.0% assumption is too high while the market has overcorrected in one go." The base-case fair value of RMB 33.5–36.9 hinges on the key premise of no downward revision of the EV investment yield assumption in the 2026 annual report: if it is cut by 50bp, 2026E EV per share falls to about RMB 59.8, and the same multiple range collapses back to RMB 29.9–32.9, near the current price — at which point this thesis fails. Peer multiple anchors (sector 0.55x, NCI 0.55x, CPIC's own 2021–2025 year-end average P/EV of 0.53x) are all independent of the current price and do not constitute circular reasoning, but note that the 28.85% H-share weight (H-share P/EV of only ~0.34x, A/H discount of 23.7%) is a friction on A-share re-rating.
The three-factor structure of NBV growth is clear: margin recovery (participating products carry low guaranteed benefits and high first-day margins, plus "reporting-bancassurance alignment" compressing bancassurance expense), volume growth in new bancassurance sales, and agents' "productivity replacing headcount" (average monthly headcount flat at 183k, but core-agent productivity up sharply). The product mix shift toward participating products (55.5% of new business) transfers part of the investment risk to customers — the core mechanism lowering the cost of new-business liabilities. EV compounding is the floor for valuation: in 2025, EV grew 9.1%, of which assumption/model changes contributed RMB 7.228bn (14.1% of the increment), adding about 1.3pt — excluding that contribution, organic growth was about 7.8%; 2026H1 EV was +3.8% vs. beginning of year (simple annualization ~7.7%). Even if the P/EV multiple never re-rates, EV compounding alone constitutes roughly 7.5%–8% of value accumulation per year.
Two constraints must be presented alongside: first, the second derivative of growth is negative — NBV growth slowed from +40.1% in 2025 to +12.7% in H1; life insurance gross premium was -1.6% YoY in H1, with a 17.5% margin below the 19.8% full-year 2025 level; with flat headcount, NBV depends entirely on the single engine of productivity, and 2027 faces high-base pressure. Second, the transmission of EV growth to shareholder returns is mediated by dividends — the 2025 cash dividend of RMB 11.063bn was only 1.7% of EV and 20.7% of parent-attributable net profit; payout is low and the solvency ratio fell 18pt in six months, so the value cushion does not automatically convert into the share price. If NBV is negative for two consecutive periods, or the 2026 annual report's EV assumption revision erases about 1.4 years of organic growth (-10.8% ÷ 7.8%), this thesis fails.
P&C is the highest-certainty piece of the group's earnings structure: a COR of 95.0% (2026H1) sits in a historically favorable range, supported by the retreat of industry expense competition + credit guarantee runoff + the transition to risk-reduction services. But three boundaries must be made explicit: ① the 95.0% is a first-half reading; second-half typhoon/flood catastrophe seasonality is heavier (the 2025 full-year 97.5% implies ~98.9% for H2), and the 2026 full-year COR is more likely to land at 96%–96.5%; ② the biggest contributor to 2025 P&C segment profit growth was in fact investment income (RMB 8.765bn, +16.0%; the annual report itself attributes it to "growth in fair-value gains and realized gains YoY"), so "underwriting improvement" cannot fully be credited for "segment profit improvement"; ③ multiple CPIC P&C grassroots branches were repeatedly penalized for "falsified financial data" during 2023–2026 (5 branch companies including Hainan and Qingyang, Changsha central sub-branch, Lianyungang, etc.; fines of RMB 250k–805k each) — immaterial in amount but a signal of data-quality discount. If the 2026 full-year COR rises above 98% or single-quarter catastrophe losses spiral, this thesis fails.
TTM dividend yield is 5.31% (last 12 months declared DPS of RMB 1.57 ÷ RMB 29.56), about 368bp above the 10Y CGB yield of 1.63%; the FY2025 basis is 3.89%. But two corrections must be stated: first, within this year's sample, the "dividend floor" logic has been falsified — the yield rose from ~3.5% at the start of the year to 5.31% as the stock fell, and the share price did not stop falling at any dividend level; a high dividend is a reason for long-term capital allocation, not a sufficient brake on declines. Second, the company's dividend policy text reads "anchored to operating profit, supplemented by dividend increases funded by positive investment contributions, subject to solvency constraints" — with 2026H1 comprehensive investment yield at only 1.8% (-0.6pt) and Q3 equity losses, the supplementary condition is unlikely to be met; if operating profit grows +5%–6% (about RMB 38.4–38.7bn) and payout stays at 30.3%, FY2026 DPS would center at about RMB 1.21 (range RMB 1.15–1.22, implying a yield of 3.9%–4.1%); prior market expectations (RMB 1.19–1.25 and above) imply a payout increase with no guarantee in the policy text. The positive signal is a marginal change in governance: Chairman Fu Fan increased his H-share holding three times this year for a cumulative 30k shares; in September directors/supervisors/senior management (Zhao Yonggang, Yu Bin, Ma Xin) bought in clusters with zero sales all year; Ping An raised its stake in CPIC H-shares again in March 2026 to 12.08% (spending HK$101m at a cost of HK$32.39, deeply underwater but still holding). If FY2026 DPS falls below RMB 1.15 (a YoY decline) or the life insurance comprehensive solvency ratio drops below 180% and materially constrains dividends, this thesis fails.
| Metric | 2023 | 2024 | 2025 | 2026H1 (latest period) |
|---|---|---|---|---|
| Operating revenue | 3,239.45 | 4,040.89 | 4,351.56 | 2,121.36 (+5.8%) |
| Parent-attributable net profit | 272.57 | 449.60 | 535.05 | 307.75 (+10.4%) |
| Recurring parent-attributable net profit | 271.35 | 449.26 | 523.30 | 297.84 (+13.6%) |
| Parent-attributable operating profit | — | ~344.2 (estimated) | 365.23 | 211.49 (+6.2%) |
| Weighted ROE | 11.4% | 16.6% | 18.0% | 9.7% (half-year) |
| New business value (NBV) | 109.62 | 132.79 (restated) | 186.09 | 107.58 (+12.7%) |
| NBV margin | 13.3% | 16.8% | 19.8% | 17.5% |
| P&C combined ratio | 97.7% | 98.6% | 97.5% | 95.0% |
| Group embedded value (period-end) | 5,294.93 | 5,620.66 | 6,133.65 | 6,369.38 |
| EV per share (RMB, period-end) | 55.04 (estimated) | 58.42 (estimated) | 63.76 | 66.21 |
| Net assets per share (RMB, period-end) | — | — | 31.41 | 33.18 |
| Net investment yield | 4.0% | 3.8% | 3.4% | 1.5% (un-annualized) |
| Total investment yield | 2.6% | 5.6% | 5.7% | 2.4% (un-annualized) |
| Comprehensive investment yield | 2.7% | 6.0% | 6.1% | 1.8% (un-annualized) |
| Group comprehensive solvency adequacy ratio (period-end) | 257% | 256% | 273% | 255% (core 191%) |
| Net operating cash flow | 1,378.63 | 1,544.04 | 1,955.23 | 1,150.80 (-4.5%) |
| DPS (RMB, incl. tax) | 1.02 | 1.08 | 1.15 | 0.42 (interim, first ever) |
Note: Insurance groups have no gross margin, capex, free cash flow, net debt/EBITDA or similar metrics; structurally inapplicable items are omitted. 2024 NBV/margin figures use the restated basis from the 2025 annual report (including CPIC Life Hong Kong).
Reasons for metric changes (management explanations for line items with YoY ≥ ±20%): 2024 parent-attributable net profit +64.9%, attributed by the company to "the impact of rising capital markets and growth in insurance service results" (2025 annual report); 2025 investment income of RMB 52.657bn, +95.7%, attributed to "increased gains on securities trading, etc." (rising capital markets); 2025 year-end cash +113.9% ("timing factors and the issuance of H-share convertible bonds"), bonds payable +120.5% ("issuance of H-share convertible bonds," a HK$15.556bn zero-coupon convertible); 2025 other comprehensive loss of -RMB 32.910bn ("fair value changes of FVOCI financial assets due to capital market volatility"); 2026H1 investment income +55.2% ("increased gains on securities trading, etc."); within 2025's EV +9.1%, valuation method, assumption, and model changes contributed +RMB 7.228bn (14.1% of the increment); 2026Q1 income tax swung from -RMB 1.545bn (a credit) to +RMB 144m, so pre-tax profit fell -11.5% while net profit rose +4.3% (fluctuations in tax-exempt income and deferred tax; not separately explained by the company).
In H1 2026, revenue was RMB 212,136 million (+5.8%), net profit attributable to parent RMB 30,775 million (+10.4%), non-recurring-adjusted net profit RMB 29,784 million (+13.6%), and operating profit RMB 21,149 million (+6.2%). Against a backdrop of low life insurance premium growth industry-wide (+1.3% for the first nine months), the company grew via margin and structure rather than scale: of NBV of RMB 10,758 million (+12.7%), new single-year regular premium grew +28.6%, participating (dividend) insurance rose to 55.5% of new business, and bancassurance new single-year regular premium +32.6%; however, total life insurance premium declined -1.6% and bancassurance channel total premium -4.6% — scale and value continued to decouple. P&C COR of 95.0% was among the best for the period, with underwriting profit of RMB 4,817 million (+35.7%). The "quality" of profit composition is moderate: operating profit was 68.7% of net profit attributable to parent, with the gap mainly from short-term investment volatility and fair-value remeasurement of convertible bond conversion rights (H1 +RMB 1,259 million non-recurring gains). After the interim report (late August), the market initially re-rated the stock on "steady results + interim dividend"; from September, the rally reversed with the equity pullback and Q3 profit concerns — exposure of reported profit to capital markets is the biggest earnings variable in 2026: sell-side forecasts Q3 standalone net profit attributable of roughly -76.3% (SWS Research, ~RMB 4.2 billion; Huatai's neutral scenario is more cautious, near a quarterly loss), and October's -7.4% share price decline has partially priced this in. The Q3 2026 report is due after market close on the date of this report; key checkpoints: 9M net profit attributable (consensus ~RMB 35 billion/-23.4%), whether cumulative NBV growth holds double digits, 9M COR, total investment yield for the first three quarters, and management's guidance on full-year dividends and equity allocation.
Business model in brief: A composite insurance group = life insurance (liability-driven investment: premiums → reserves → investment returns covering liability costs; profit = insurance service results + investment results) + P&C insurance (underwriting profit + investment returns, with COR as the core yardstick) + asset management (AUM RMB 3.89 trillion, third-party fee income +41.1%, capital-light). Recurring revenue is strong: renewal premium is 79.0% of agent channel premiums; life insurance runs on a dual engine of "in-force policy cash flow + new business value"; P&C is mostly one-year policies, with pricing power diverging after the comprehensive motor reform. Pricing power is constrained by regulation (pricing rate caps); the company substitutes direct price increases with product mix shifts (floating returns on participating products) to sustain margins — in 2026H1, participating products were 55.5% of new business while margin still rose 2.5pt, the core lever in a low-rate environment.
Cash content of earnings and profit composition (insurance-specific framework in lieu of CapEx/FCF): the "collect premiums first, pay claims later" model keeps OCF/net profit attributable persistently at 3.4–5.1x (2023–2026H1: 5.06/3.43/3.65/3.74), showing strong cash generation; but cash flow size is determined by underwriting scale and does not directly reflect earnings quality. More relevant is profit composition quality — operating profit (excluding short-term investment volatility and one-off items) was 68.7% of net profit attributable (2026H1); life insurance "investment results" of RMB 8,777 million was 35.8% of life insurance pre-tax profit, so profit is sensitive to investments. The gap between non-recurring-adjusted and reported profit is mainly convertible bond remeasurement (H1 +RMB 1,259 million) and one-off consolidation gains (RMB 1,603 million from Rui-Yong-Jing in 2025), with a difference of <5% — no sign of one-off window dressing.
Three-spread test: Expense spread — after the "report-bank fee alignment" policy, channel costs fell systematically (P&C expense ratio 27.1%, -0.7pt; bancassurance expense ratio down sharply; 2025H2 first-year commission per core agent +22.0% indicating improved expense efficiency) — the largest current positive marginal contributor. Mortality spread — declining share of protection-type products erodes it, with participating products replacing fixed mortality spread via a "sharing mechanism." Interest spread — the largest risk exposure: EV assumption of 4.0% vs net investment yield of 3.4% (2025) and declining for three consecutive years; new business costs have fallen to 2.0% for conventional products / 1.75% + floating for participating; the liability-asset gap is narrowing but the stock gap persists (see industry-specific chapter for details).
Capital returns and solvency: 2025 weighted ROE of 18.0% (11.4% in 2023 → rising consecutively) shows strong internal capital generation; but the group's comprehensive solvency adequacy ratio fell -18pt within six months to 255% (core -15pt to 191%), life insurance comprehensive to 209% (-19pt), and actual capital of RMB 588.4 billion declined RMB 8.2 billion in six months — under dual pressure from equities and rates, solvency is the hard constraint valve on dividends and capital release.
Red flags: ① High profit dependence on capital markets (2024 +64.9%/2025 +19.0% both attributed to capital markets; 2026 will test this in reverse); ② High NBV growth comes with product mix shifts — guaranteed benefits down, profit sources more dependent on future dividend realization rates; ③ Rising equity allocation center of gravity (core equity ratio 13.9%, +0.5pt) amplifies volatility in profit and solvency.
Consistency of words and deeds: pragmatic operations, weak shareholder-return execution — verdict "partially delivered." Evidence 1: The 2024 annual report promised "Phase II 'North Star' plan deepening customer operations and multi-channel upgrades"; actual 2025 NBV +40.1%, margin +3.2pt, bancassurance regular premium +43.2% — delivered. Evidence 2: The 2026 interim presentation promised "striving for steady full-year NBV growth"; H1 NBV +12.7%, COR improved 1.3pt — being delivered. Evidence 3 (negative): On April 8, 2025, Chairman Fu Fan proposed an A-share buyback with own funds; 18 months of zero execution, 9 investor questions on the SSE e-interaction platform within 8 months (investor wording already includes "is this deceiving shareholders"), and the company's replies have consistently been "nothing to disclose" — clearly undelivered with no timeline commitment.
Shareholder-friendliness: neutral to friendly. Positives: DPS rising for three consecutive years (1.02→1.08→1.15 yuan, +6.5%), cumulative dividends over RMB 130 billion since listing, first-ever interim dividend in 2026 (frequency optimization), directors/supervisors/senior management only buying and never selling all year (Chairman Fu Fan increased H-share holdings by 30,000 shares; Zhao Yonggang/Yu Bin/Ma Xin buying intensively in September). Negatives: Payout ratio declined three years running (36.0%→23.1%→20.7%), and anchoring to operating profit makes dividend growth systematically lower than net profit growth; no buyback execution; 2025 issuance of HK$15.556 billion zero-coupon H-share convertible bonds (due 2030, potential dilution 4.13%, conversion price HK$36.89, now deeply out-of-the-money); a dilution track record including the 2020 GDR and the 2012 H-share private placement.
Risk signals: Dense executive turnover — Chief Actuary Zhang Yuanhan departed in October 2025, Chief Investment Officer Su Gang replaced by Liu Long, Vice Chairman Lu Qiaoling resigned for age reasons in August 2026; repeated 2023–2026 penalties of grassroots P&C branches for "falsified financial data," while the 2025 annual report's "penalties and rectification" section states "nothing to disclose" — completeness of compliance disclosure is questionable (the company also gave no direct response to IR inquiries about the Hunan branch incident's accountability outcomes).
2025 annual report segment disclosures (insurance has no gross-margin concept; COR/margin used as substitutes):
| Segment | Revenue (RMB 100mn) | Share | Segment net profit (RMB 100mn) | YoY | One-line business logic |
|---|---|---|---|---|---|
| Life & health insurance | 2,155.98 | 49.5% | 423.55 | +17.2% | Group's main profit engine (76.5% of segment profit), driven by NBV and CSM amortization |
| Property & casualty | 2,101.17 | 48.3% | 98.64 | +33.7% | Underwriting profit inflection: COR 97.5%, credit insurance cleanup, motor/non-motor both improving |
| Asset management | 48.46 | 1.1% | 19.80 | +68.7% | AUM RMB 3.89 trillion, third-party fee income +41.1%, capital-light supplement |
| Others & eliminations | ~46 | ~1% | — | — | HQ/eliminations, not an operating entity |
Life insurance is the profit mainstay: its revenue share is close to P&C's (49.5% vs 48.3%), but segment net profit of RMB 42.355 billion is ~76.5% of the segment total — life insurance contributes the bulk of group profit, and its NBV growth and investment yield are the first-order valuation variable; P&C provides an earnings stabilizer (underwriting profit RMB 4.836 billion +81.0%), and asset management is a capital-light option. 2026H1 life operating profit RMB 15.887 billion (+5.9%), CSM balance RMB 364.308 billion (+3.2% vs year start) — the "reservoir" of life insurance profit is still deepening. The source of the structural difference: life insurance manages liabilities with 10+ year durations and complex profit sources; P&C underwrites one-year policies with COR directly marking underwriting profitability — the business models differ greatly, and consolidated statements can mask the mismatch between life insurance investment exposure and the P&C underwriting cycle.
Accounting red flags:
Cross-period consistency:
Overall judgment: no profit-manipulation-level financial engineering detected, but the combination of discretionary room in EV actuarial assumptions + grassroots compliance blemishes + equity exposure amplifying profit volatility warrants an 80% haircut on reported statements — this is precisely where E4 and C1 (EV discount) are two sides of the same coin.
Current price RMB 29.56 (2026-10-27 close); total shares 9.62034 billion (A-shares 71.15%/H-shares 28.85%); total market cap on the A-share anchor basis RMB 284.377 billion (A/H split-cap basis ~RMB 264.9 billion: A-shares RMB 202.3bn + H-shares HK$26.54 × 0.84991 ≈ RMB 22.56/share × 2.7753bn shares ≈ RMB 62.6bn; H at a 23.7% discount to A).
| Multiple | Current | Percentile | Peer comparison |
|---|---|---|---|
| P/EV (2026H1 EV per share RMB 66.21) | 0.446 | ~5% over 1Y, 15–25% over 3Y, 25–35% over 5Y (historical range 0.36–0.75) | Lowest of the big five: China Life 0.67 / Ping An 0.64 / NCI 0.55 / sector 0.55 (2026-08) |
| P/B (BVPS RMB 33.18) | 0.89 | 3% over 3Y, 6% over 5Y, 3% over 10Y | Below book |
| PE(TTM) | 5.04 | 0% over 10Y | Distorted, reference only: LTM doubly distorted by 2025 bull-market high base + 2026H2 equity rout |
| Dividend yield TTM | 5.31% | — | NCI 5.36% / Ping An 5.13% / China Life 2.44% |
Note: peer multiples based on each company's end-2025 EV (reporting dates not fully aligned, as noted); PE is not a headline metric for insurers (earnings not representative; EV/PB is actuarial-based and decoupled from current-period P&L, so percentiles are valid).
Reverse-engineering: market cap RMB 284.377bn < net assets attributable RMB 319.196bn; the RMB 34.8bn gap = an implied write-down of ~114% of VIF (RMB 250.765bn) — i.e., VIF fully zeroed out, plus an extra 11% discount on net assets. Linear extrapolation from 2025 annual report sensitivities (EV sensitivity to -50bp ≈ -10.8%) cross-checked against peer-implied returns, the current price implies a long-term investment yield of about 1.2%–1.4% — below the 10Y government bond at 1.63%, i.e., the market believes "CPIC's in-force book has a long-term blended investment capability that underperforms the risk-free rate, permanently." Reality: the company's 3-year average investment yield is 4.9% (company basis, including equity mark-to-market gains), 2025 net investment yield 3.4%, reported assumption 4.0% — the current price demands "permanently 1.4%," while reality is "achieved 3.4%–4.9%, trending down." Neither side is exactly right, but market pricing is further from reality. Acknowledgment: this implied estimate may overstate pessimism via linear extrapolation; the true implied yield could be as high as ~2%; even so, it remains significantly below the reported assumption, so the directional conclusion stands.
| Scenario | Probability | Fair range | Core assumptions | vs current price |
|---|---|---|---|---|
| Bear | 25% | 23.3–26.6 | 10Y below 1.5% + renewed Q4 equity rout + annual-report EV assumption cut (-50bp → VIF -27.4%); P/EV 0.35–0.40 × cut EV per share ≈ 59.8 | -21%~-10% |
| Base | 50% | 33.5–36.9 | Rates stabilize at 1.6–1.8% + NBV high-single to low-double-digit growth + no assumption cuts; P/EV 0.50–0.55 × 2026E end EV per share 67.04 | +13%~+25% |
| Bull | 25% | 40.5–47.3 | Rates back above 2.2% + equity recovery → sector re-rating; P/EV 0.60–0.70 (precedents: CPIC 0.657, China Life 0.675 realized at end-2025) | +37%~+60% |
Basis for base-case exit multiple anchors: sector 0.55x (industry basis, 2026-08), NCI's current 0.55x, CPIC's own 2021–2025 year-end P/EV average of 0.53x — all three anchors independent of current price; the current 0.446x is for comparison only. Sensitivity caveat (hedged statement): if the March 2027 annual report cuts the EV investment yield assumption by 50bp, 2026E EV per share falls to ~59.8 and the same multiple range collapses back to 29.9–32.9, near the current price — this is the single biggest risk to the base case. External anchor comparison: no sell-side price-side bearish targets (all 60 ratings in the past 90 days buy/overweight); the bearish anchor exists only on the earnings side (SWS 9M26 -23.4%, Huatai neutral scenario a Q3 standalone loss); the H-share P/EV of 0.34x is a market-formed bearish coordinate, broadly comparable to this report's bear case of 0.35–0.40x (accounting for A/H structural discount differences); the bullish anchor (consensus target median RMB 48.5, BOCOM International HK$44) predates the Q3 equity rout and is too stale to cite directly. The H-share convertible (potential dilution 4.13%) creates conversion friction in the bull case.
| Period | Revenue | Net profit attributable | Drivers |
|---|---|---|---|
| FY2026E | RMB 400.0–423.3bn (-8%~-3%) | RMB 37.5–41.0bn (-30%~-23%), EPS 3.90–4.26 | H2 NBV +8% (full year ~RMB 20.0–20.6bn); equity rout drags total investment income (Q3 standalone ~RMB 4.2bn vs a 17.7bn high base in 2025Q3); operating profit still ~+6% (~RMB 38.8bn) |
| FY2027E | RMB 410.0–440.0bn | RMB 42.0–50.0bn | NBV high-single-digit growth; no 2026-style equity high-base distortion; reported profit converges toward operating profit |
Method note: significantly below sell-side consensus (FY26 EPS RMB 6.01/~RMB 57.8bn) because consensus has not been revised in the past 90 days and implies a Q4 standalone RMB 22.8bn (+192%), arithmetically unattainable; this forecast also embeds assumptions on the Q4 equity path (a Q4 rebound would prove both sides wrong). The EV assumption-cut risk (-50bp → VIF -27.4%) is not included in the net profit range. The next report must be reconciled against this.
Undervalued: a severe mismatch between quality (ROE 18%, NBV double digits, COR 95%, operating profit +6%) and price (0.45x P/EV, below book, implied yield below government bonds); the re-rating path is mean reversion of the multiple toward 0.50–0.55 rather than growth delivery. Target price RMB 33.5–36.9 (base), margin of safety ~13.3% (base-case fair-value floor vs current price); probability-weighted expected value ~RMB 34.81 (+17.8%). Assess quality and price separately: quality is strong (first-tier earnings quality and transformation execution); price is deeply discounted but conditional — the conditions are "no assumption cuts + no rate break"; hence the stance is cautiously bullish rather than decisively bullish.
In 2025, China's insurance industry recorded original premium income of RMB 6.12 trillion, up 7.43% YoY (National Financial Regulatory Administration), of which life insurers contributed RMB 4.36 trillion (+8.9%) and P&C insurers RMB 1.76 trillion (+3.9%); total industry assets reached RMB 41.32 trillion (+15.06% vs. end-2024). Insurance penetration is approximately 4.37% (RMB 6.12 trillion ÷ 2025 GDP of RMB 140.19 trillion, NBS preliminary estimate) and insurance density approximately RMB 4,356 per capita—still a structural gap versus mature global markets (penetration 6–8%). The regulator's "New National Ten Guidelines" (GF〔2024〕No. 21) set the tone for an initially formed high-quality development framework by 2029 and a basically formed new insurance industry landscape by 2035. Growth trajectory: original premiums rose from RMB 4.49 trillion in 2021 to RMB 6.12 trillion in 2025, a five-year CAGR of about 6.4%; the acceleration in 2024–2025 was mainly due to front-loaded "sales rush before pricing rate cuts"—Q4 2025 life insurance single-quarter premiums rose only +0.3% YoY (Soochow Securities), and in the first 9 months of 2026 industry premiums grew only +0.9% (life +1.3%, P&C -0.56%), marking the industry's entry into a "volume down, price stable" transition period. Over the next 3–5 years, the mainstream expectation for premium growth is a 5–8% midpoint, driven by the third pillar of pensions (expansion of personal pension accounts), health insurance expansion, and savings products' comparative advantage over deposits (guaranteed rate 2.0% vs. declining deposit rates); the digestion of short-term front-loading will take 2–4 quarters.
The uniqueness of the insurance value chain lies in "upstream: funds and capital; midstream: actuarial science and distribution; downstream: customers' lifetime cash flow": product design (actuarial pricing constrained by guaranteed-rate caps: par 2.0% / participating 1.75% / universal 1.0%, effective September 2025) → channel sales (agents / bancassurance / group & government / brokers) → underwriting operations → asset management (the main profit source). This round of regulatory restructuring has redrawn value distribution: "report-and-execution alignment" (bancassurance from August 2023 → all channels from August 2024 → upgraded bancassurance expense management in March 2026) writes expense assumptions into hard actuarial constraints, systematically returning channel expenses to insurers—bancassurance has shifted from "volume contributor" to "value contributor" (2025: Ping An bancassurance NBV +138%, CPIC +102.3%, China Life bancassurance total premiums RMB 110.874 billion, +45.5%). CPIC sits at the midstream of the full "product + channel + investment" chain: pricing to downstream customers is capped by regulation (no independent pricing power, but in a low-rate environment savings products' scarcity relative to deposits rises); bargaining power over upstream channels has strengthened significantly thanks to report-and-execution alignment; value (profit) is mainly retained in underwriting sources and the investment end. The P&C chain is similar: after the comprehensive auto insurance reform (September 2020), competition shifted from expenses to pricing and risk-reduction capability; non-auto insurance entered "comprehensive governance" in September 2025 and price wars are receding.
Life insurance: demand is "pulse-like" (rate-comparison driven: sales rush before guaranteed-rate cuts, then a fall-back); on the supply side, products are shifting toward participating policies (guaranteed + floating) to match low rates; competition focuses on "soft competition" in participating realization rates / service / health & eldercare ecosystems, and channel competition has intensified since the relaxation of bancassurance's "1+3" branch limit. Landscape: China Life total premiums RMB 729.887 billion, market share about 16.7%; Ping An second, CPIC third (by original premiums); the top five (China Life / Ping An / CPIC / NCI / PICC Life) together hold about 40%, with the head structure stable. P&C: CR3 (PICC / Ping An / CPIC) posted combined 2025 insurance business income of about RMB 1.1 trillion, 62.91% of the industry (63.96% in 2024, a slight decline from head players' deliberate restraint); profit CR3 = 76.61% (the "Big Three" net profit RMB 61.93 billion)—underwriting profitability is concentrating in the top players. Entry barriers: licensing (strict regulatory approval), solvency capital requirements, accumulated actuarial data, national distribution networks, and long-duration asset-liability matching capability. Substitutes: savings insurance vs. deposits / wealth-management products / government bonds (falling rates weaken substitutes' returns, favoring savings insurance); health insurance vs. social health insurance / Huiminbao; autonomous driving may in the long run reshape the auto insurance risk pool.
The industry is in a transition period of a "new low-rate cycle": on the liability side, 2025 NBV grew strongly across the board (the five A-share majors averaged +45.4%), with participating insurance and bancassurance established as twin engines; on the stock-price side, after the sector's big 2025 rally (+30.5%), 2026 has seen pullback digestion (CPIC YTD -34.4%, sector P/EV about 0.55x at historical lows)—a mismatch between improving fundamentals and valuation bubble-squeezing. Leading indicators: ① the guaranteed-rate research value (rebounded to 1.94% in 2026Q2, up for two consecutive quarters, just 6bp below the 2.0% cap, no further cut to be triggered this year—a pricing stabilization signal; Zhongtai estimates about 1.86% by end-2026); ② monthly original premium growth; ③ participating products' share of new business; ④ the 10Y government bond yield vs. insurers' investment yields; ⑤ P&C combined ratio. Regulatory direction is neutral-to-positive: the New National Ten Guidelines emphasize strict regulation and risk prevention; the dynamic guaranteed-rate adjustment mechanism (implemented January 2025, triggered July, effective September) makes liability costs structurally decline (par products cumulative -150bp); long-cycle assessment of insurance funds (state-owned insurers' current-year ROE weight ≤30%, 3–5 year weight ≥60%; large insurers to invest 30% of new premiums in A-shares) plus raised equity allocation caps guide long-term capital into equities; IFRS17 (from 2023) restructures reporting logic. The cost is the short-term fall-back of new-business pulses and reduced product attractiveness.
| Company | Close | P/EV | 2025 NBV Growth | 2025 ROE | Dividend Yield (2025 DPS) | Key Differences vs. CPIC |
|---|---|---|---|---|---|---|
| China Pacific Insurance (CPIC) | RMB 29.56 | 0.45 (2026H1 EV) | +40.1% | 18.0% | 3.89% (TTM 5.31%) | Rare combined license: #3 in life + #3 in P&C; first tier in value growth |
| China Life | RMB 35.10 | 0.67 | +35.7% | 27.81% | 2.44% | Pure life leader with the deepest scale and channel reach; lowest dividend yield |
| Ping An | RMB 52.61 | 0.62–0.64 | +29.3% | 14.0% | 5.13% | Integrated finance + tech ecosystem; raised its CPIC H-share stake to 12.08% in 2026 |
| New China Life (NCI) | RMB 50.95 | 0.55 | +57.4% | 32.48% | 5.36% | Pure life with the greatest equity beta (more stock-market dependent than CPIC); no P&C stabilizer |
| PICC | RMB 7.35 | P/EV N/A (P&C core) | PICC Life +64.5% | 16.1% | — | #1 P&C market share (31.6%); COR 97.6% slightly below CPIC P&C |
CPIC's P/EV is the lowest of the five (33% discount to China Life), while its 2025 NBV growth, value-margin improvement and COR improvement are all first tier—the valuation gap mainly reflects the market's pricing of its equity exposure and H-share ratio (28.85%; H-shares P/EV only 0.34x), not inferior operating standing.
"A value leader among chasers": life insurance gross premiums RMB 295.855 billion, share about 6.8% (#3 by scale); NBV RMB 18.609 billion, value margin 19.8% (among the largest improvements among the A-share five); P&C share about 11.4% (#3), COR 97.5% its best since 2023, behind only Ping An P&C's 96.8%. Share trend: "value share rising, scale share stable." Moats: synergy across P&C + life + pensions + asset management (AUM RMB 3.89 trillion, 190 million customers); dual-wheel diversified channels (stable agent headcount with rising quality + bancassurance value shift, NBV +102.3%); early-mover participating transformation without sacrificing growth (vs. China Taiping: ~90% participating share but NBV only +2.7%); large health & eldercare ecosystem (CPIC Homes: 15 campuses in 13 cities; commercial pension annuity new business +93.4%); stable governance with dispersed state-owned ownership. Industrial capital endorsement: Ping An's two rounds of stake accumulation to 12.08%.
For insurance stocks, the decisive factors lie not in the generic financial framework but along three lines: new business value (NBV) × the three margins (spread / expense / mortality) × the credibility of embedded value (EV).
NBV growth logic: NBV = new premiums × value margin. 2025's industry-wide strong NBV growth (five majors averaging +45.4%) had three drivers: ① value-margin repair (CPIC 19.8%, +3.2pt; participating products' lower guaranteed benefits → higher day-one margins; bancassurance value margin repaired from near zero after report-and-execution alignment); ② bancassurance new-business volume; ③ agent productivity replacing headcount (CPIC headcount -1.6% but core agent productivity +17.1%). In 2026 the midpoint falls back: the guaranteed-rate cut front-loaded 2025Q4 new business (single-quarter premiums +0.3%), and listed insurers' 2026H1 NBV turned to single-digit to low-teens steady growth (CPIC +12.7%). The key divide is whether the value margin can hold above 19%—it determines whether NBV growth follows a healthy "volume down, price up" model or relies on pulse-driven pre-cut sales rushes.
Three-margin framework (current profit structure): expense margin—report-and-execution alignment is the largest incremental positive, returning channel expenses; mortality margin—shrinking protection mix keeps eroding it, with participating products replacing fixed mortality margins via a "shared mechanism"; spread margin—the largest risk exposure: the -150bp guaranteed-rate cut plus participating transformation partially transfers new-business spread risk to customers (Taiping's NBV rate sensitivity 25.9%→5.7% as an industry sample), but in-force policies' spread losses are still being digested (CPIC fixed-income duration of 11.7 years hedges reinvestment risk). The industry's profit source is migrating from "spread dependence" toward "expense margin + participating sharing"—the degree of completion determines whether insurance stocks deserve a "spread-loss discount" or a "value-growth premium."
Credibility controversy of the EV valuation framework (insurance stocks' self-fulfilling discount mechanism): EV = adjusted net assets + value of in-force business (VIF), with VIF dependent on assumptions for investment yield / mortality / lapse rates. The market applies a "discount prism": ① assumption credibility—the market-implied long-term investment yield backed out of current P/EV is about 2.2% for Ping An (Huachuang / Kaiyuan estimates), below its actual net investment yield of 3.0%–3.6%; CPIC's 0.45x implies about 1.4%; ② the historical spread-loss legacy (high-guaranteed-rate in-force policies from the 1990s); ③ under IFRS17, net profit decouples from EV, and FVTPL equity volatility amplifies profit swings (2025's five majors' +22.4% net profit mainly from investment income), weakening EV predictability; ④ H-share liquidity discount (CPIC H 0.34x vs. A 0.45x). Repair triggers: long-end rate stabilization, validated participating realization rates, and continued delivery of EV growth; conversely, if rates trend down and EV assumptions are forced lower, the discount self-fulfills—precisely why this report sets "no assumption downgrade" as a baseline-scenario precondition. The regulator's mitigation progress bar: new-business costs have fallen to 2.0% par / 1.75% participating + floating; the 2026 research value rebounded to 1.94% with no further cut to be triggered this year; the gap between liability and asset yields is narrowing (CPIC's 2025 comprehensive investment yield of 6.1% significantly exceeds new-business liability cost); the risk lies in the in-force book: net investment yield is still declining (3.4%, -0.4pt), and if long-end rates trend below 2% and investment yields drift toward 2.5%, the discount will self-fulfill.
Solvency (the capital-constraint valve): group comprehensive 255% / core 191% (end-2026H1, -18pt / -15pt half-yearly), life comprehensive 209% / core 143%, P&C comprehensive 240%—still far from regulatory red lines (comprehensive 100% / core 50%), but the slope determines the capital headroom for dividends: if the 10–20pt half-yearly decline continues, life solvency will approach the 180% psychological line by mid-2027, and the "operating-profit-anchored" dividend policy would face substantive constraints. Watch each quarterly solvency report's "interest rate and capital market changes" impact on actual capital.
Overall verdict: cautiously bullish, confidence 0.60, time horizon 12–18 months. CPIC is currently a contrarian position with "high quality + deep price discount + clearly defined preconditions": the market has priced in "a world of 1.4% rates in perpetuity," while operations (NBV +12.7%, COR 95.0%, operating profit +6.2%, EV compounding 7.8%) still run on a track of "assuming 4.0%, delivering 3.4%"; the base case fair value is RMB 33.5–36.9 with a safety margin of about 13.3%, an unfavorable odds structure (downside to bear-case midpoint -15.6% vs. upside to base-case midpoint +19.1% and bull-case midpoint +48.5%). The reasons confidence is only 0.60: direction depends on two exogenous variables—"rate stabilization + no assumption downgrades"—and the actual Q3 results (released after market close on this report's date) still span a range between SWS (single-quarter ~RMB 4.2 billion) and Huatai (single-quarter loss)—this judgment does not pre-set tonight's outcome; it will be reassessed on the actual disclosed figures.
Strategy statement: at current prices the stock offers allocation value, suited to capital with dividend return as the base-case logic and valuation repair as the source of elasticity; do not chase before catalysts are validated, and if the 2027 annual report downgrades EV assumptions, reassess rather than buy the dip.
Risk and catalyst reminders (presented in writing; conditions already in the monitoring system): upside catalysts—Q3 report clearing the overhang with NBV holding double digits (2026-10-28); guaranteed-rate research value rebounding a third consecutive quarter (2026-11); announcement and execution of a buyback plan (any time); Ping An's stake crossing 13% (irregular); 2026 DPS ≥ RMB 1.15 (2027-03). Downside risks—10Y falling below 1.5%; annual report downgrading EV investment yield assumptions (VIF -27.4% / -50bp); Q4 equities falling another 10%+ (after-tax impact ~RMB 32.2 billion, solvency down to ~236%); two consecutive periods of negative NBV growth; life comprehensive solvency falling below 180%. Governance watch items: whether the buyback's "nothing to disclose" language softens, whether grassroots compliance penalties escalate, and convertible bond conversion progress.
Data and basis notes: this report's price anchor is the 2026-10-27 A-share close of RMB 29.56 (a completed trading day); EV / net assets are 2026H1-end values, peers' EV are end-2025 values (reporting dates noted); the 2026 Q3 report was disclosed after market close on this report's date (2026-10-28), and all Q3 references in this report are sell-side expectations, not disclosed facts. FX: HKD 1 = RMB 0.84991 (2026-10-28). Financial data sourced from the company's 2023–2025 annual reports and 2026 Q1 and interim reports (cninfo); industry data sourced from the National Financial Regulatory Administration, the National Bureau of Statistics, and public reporting.